The Rationale and Design of the Reducing Pathology in Alzheimer’s Disease through Angiotensin TaRgeting (RADAR) Trial
Open accessAbstract
BACKGROUND: Anti-hypertensives that modify the renin angiotensin system may reduce Alzheimer's disease (AD) pathology and reduce the rate of disease progression. OBJECTIVE: To conduct a phase II, two arm, double-blind, placebo-controlled, randomized trial of losartan to test the efficacy of Reducing pathology in Alzheimer's Disease through Angiotensin TaRgeting (RADAR). METHODS: Men and women aged at least 55 years with mild-to-moderate AD will be randomly allocated 100 mg encapsulated generic losartan or placebo once daily for 12 months after successful completion of a 2-week open-label phase and 2-week placebo washout to establish drug tolerability. 228 participants will provide at least 182 subjects with final assessments to provide 84% power to detect a 25% difference in atrophy rate (therapeutic benefit) change over 12 months at an alpha level of 0.05. We will use intention-to-treat analysis, estimating between-group differences in outcomes derived from appropriate (linear or logistic) multivariable regression models adjusting for minimization variables. RESULTS: The primary outcome will be rate of whole brain atrophy as a surrogate measure of disease progression. Secondary outcomes will include changes to 1) white matter hyperintensity volume and cerebral blood flow; 2) performance on a standard series of assessments of memory, cognitive function, activities of daily living, and quality of life. Major assessments (for all outcomes) and relevant safety monitoring of blood pressure and bloods will be at baseline and 12 months. Additional cognitive assessment will also be conducted at 6 months along with safety blood pressure and blood monitoring. Monitoring of blood pressure, bloods, and self-reported side effects will occur during the open-label phase and during the majority of the post-randomization dispensing visits. CONCLUSION: This study will identify whether losartan is efficacious in the treatment of AD and whether definitive Phase III trials are warranted.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Angiotensin II, a product of ACE function, mediates a number of neuropathological processes in Alzheimer's disease and is now a target for intervention in phase II clinical trials.
“angiotensin II, a product of ACE function, mediates a number of neuropathological processes in Alzheimer’s disease84 and is now a target for intervention in phase II clinical trials of Alzheimer’s disease85.”
From Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (2019) · cites this paper as [85]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Using thematic analysis in psychology
Braun, V., & Clarke, V. (2006) · Qualitative Research in Psychology · doi:10.1191/1478088706qp063oa · Cited by 194,414 · see citing works
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915 · see citing works
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568 · see citing works
Global prevalence of dementia: a Delphi consensus study
Ferri, C. P., Prince, M. J., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K. S., Hasegawa, K., Hendrie, H. C., Huang, Y., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67889-0 · Cited by 5,336 · see citing works
Sample size in qualitative research
Sandelowski, M. (1995) · Research in Nursing & Health · doi:10.1002/nur.4770180211 · Cited by 4,372 · see citing works
The Alzheimer’s disease neuroimaging initiative (ADNI): MRI methods
Jack, C. R., Bernstein, M. A., Fox, N. C., Thompson, P., Alexander, G., Harvey, D., Borowski, B., Britson, P. J., L. Whitwell, J., Ward, C., et al. (2008) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.21049 · Cited by 4,347 · see citing works
Self-citationA new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175 · see citing works
The clinical use of structural MRI in Alzheimer disease
Frisoni, G. B., Fox, N. C., Jack, C. R., Scheltens, P., & Thompson, P. M. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.215 · Cited by 2,113 · see citing works
Self-citationTwo Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · see citing works
Self-citationScheltens, P., Leys, D., Barkhof, F., Huglo, D. G., Weinstein, H. C., Vermersch, P., Kuiper, M. A., Steinling, M., Wolters, E. C., & Valk, J. (1992) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.10.967 · Cited by 1,781 · see citing works
Kivipelto, M., Helkala, E.-L., Laakso, M. P., Hänninen, T., Hallikainen, M., Alhainen, K., Soininen, H., Tuomilehto, J., & Nissinen, A. (2001) · BMJ · doi:10.1136/bmj.322.7300.1447 · Cited by 1,618 · see citing works
Pathological verification of ischemic score in differentiation of dementias
Rosen, W. G., Terry, R. D., Fuld, P. A., Katzman, R., & Peck, A. (1980) · Annals of Neurology · doi:10.1002/ana.410070516 · Cited by 1,273 · see citing works
Factors affecting therapeutic compliance: A review from the patient’s perspective
Li, S.-C. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s1458 · Cited by 1,266 · see citing works
Midlife blood pressure and dementia: the Honolulu–Asia aging study☆
Launer, L. J., Ross, G. W., Petrovitch, H., Masaki, K., Foley, D., White, L. R., & Havlik, R. J. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00096-8 · Cited by 1,008 · see citing works
Smith, S. C., Lamping, D. L., Banerjee, S., Harwood, R., Foley, B., Smith, P. B., Cook, J., Murray, J., Prince, M. J., Levin, E., et al. (2005) · Health Technology Assessment · doi:10.3310/hta9100 · Cited by 651 · see citing works
Bucks, R. S., Ashworth, D. L., Wilcock, G. K., & Siegfried, K. (1996) · Age and Ageing · doi:10.1093/ageing/25.2.113 · Cited by 581 · see citing works
Li, N.-C., Lee, A., Whitmer, R. A., Kivipelto, M., Lawler, E., Kazis, L. E., & Wolozin, B. (2010) · BMJ · doi:10.1136/bmj.b5465 · Cited by 486 · see citing works
Plasma Aβ1–40 and Aβ1–42 and the risk of dementia: a prospective case-cohort study
van Oijen, M., Hofman, A., Soares, H. D., Koudstaal, P. J., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70501-4 · Cited by 458 · see citing works
The Neuropharmacological Basis for the Use of Memantine in the Treatment of Alzheimer's Disease
Rogawski, M. A., & Wenk, G. L. (2003) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2003.tb00254.x · Cited by 438 · see citing works
Freeborough, P. A., & Fox, N. C. (1997) · IEEE Transactions on Medical Imaging · doi:10.1109/42.640753 · Cited by 384 · see citing works
Self-citationMiners, J. S., Baig, S., Palmer, J. C., Palmer, L. E., Kehoe, P. G., & Love, S. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00132.x · Cited by 380 · see citing works
Self-citationStroke and the Risk of Alzheimer Disease
Honig, L. S., Tang, M., Albert, S. M., Costa, R., Luchsinger, J. A., Manly, J. J., Stern, Y., & Mayeux, R. P. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1707 · Cited by 344 · see citing works
Correlation between rates of brain atrophy and cognitive decline in AD
Fox, N. C., Scahill, R. I., Crum, W. R., & Rossor, M. N. (1999) · Neurology · doi:10.1212/wnl.52.8.1687 · Cited by 338 · see citing works
Self-citationBuée, L., Hof, P. R., Bouras, C., Delacourte, A., Perl, D. P., Morrison, J. H., & Fillit, H. M. (1994) · Acta Neuropathologica · doi:10.1007/bf00294173 · Cited by 331 · see citing works
Wang, J., Ho, L., Chen, L., Zhao, Z., Zhao, W., Qian, X., Humala, N., Seror, I., Bartholomew, S. R., Rosendorff, C., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31547 · Cited by 331 · see citing works
Update on hypertension and Alzheimer's disease
Skoog, I. G., & Gustafson, D. (2006) · Neurological Research · doi:10.1179/016164106x130506 · Cited by 287 · see citing works
Interactive algorithms for the segmentation and quantitation of 3-D MRI brain scans
Freeborough, P. A., Fox, N. C., & Kitney, R. I. (1997) · Computer Methods and Programs in Biomedicine · doi:10.1016/s0169-2607(97)01803-8 · Cited by 276 · see citing works
Self-citationGoldberg, A. I., Dunlay, M. C., & Sweet, C. S. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80413-5 · Cited by 274 · see citing works
Angiotensin II AT1 Receptor Blockade Ameliorates Brain Inflammation
Benicky, J., Sánchez-Lemus, E., Honda, M., Pang, T., Orecna, M., Wang, J., Leng, Y., Chuang, D.-M., & Saavedra, J. M. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.225 · Cited by 254 · see citing works
Carmichael, O. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.284 · Cited by 248 · see citing works
Leung, K. K., Barnes, J., Ridgway, G. R., Bartlett, J. W., Clarkson, M. J., Macdonald, K. E., Schuff, N. W., Fox, N. C., & Sebastien Ourselin, A. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2010.03.018 · Cited by 244 · see citing works
Self-citationAβ1–40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation
Niwa, K., Younkin, L. H., Ebeling, C., Turner, S. K., Westaway, D. A., Younkin, S. G., Ashe, K. H., Carlson, G. A., & Iadecola, C. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.17.9735 · Cited by 244 · see citing works
Cardoso, M. J., Leung, K. K., Marc Modat, A., Shiva Keihaninejad, A., Cash, D. M., Barnes, J., Fox, N. C., & Sebastien Ourselin, A. (2013) · Medical Image Analysis · doi:10.1016/j.media.2013.02.006 · Cited by 238 · see citing works
Self-citationSmith, J. R., Mugford, M., Holland, R., Candy, B., Noble, M., Harrison, B. D., Koutantji, M., Upton, C., & Harvey, I. M. (2005) · Health Technology Assessment · doi:10.3310/hta9230 · Cited by 232 · see citing works
Anderson, C., Teo, K., Gao, P., Arima, H., Dans, A., Unger, T., Commerford, P., Dyal, L., Schumacher, H., Pogue, J., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70250-7 · Cited by 216 · see citing works
Davies, N. M., Kehoe, P. G., Ben-Shlomo, Y., & Martin, R. M. (2011) · Journal of Alzheimer’s Disease · doi:10.3233/jad-2011-110347 · Cited by 212 · see citing works
Self-citationChan, D., Janssen, J. C., Whitwell, J. L., Watt, H., Jenkins, R., Frost, C. D., Rossor, M. N., & Fox, N. C. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14469-8 · Cited by 204 · see citing works
Self-citationLehmann, D. J., Cortina-Borja, M., Warden, D. R., Smith, A. D., Sleegers, K., Prince, J. A., van Duijn, C. M., & Kehoe, P. G. (2005) · American Journal of Epidemiology · doi:10.1093/aje/kwi202 · Cited by 199 · see citing works
Self-citationZou, K., Yamaguchi, H., Akatsu, H., Sakamoto, T., Ko, M.-H., Mizoguchi, K., Gong, J.-S., Yu, W., Yamamoto, T., Kosaka, K., et al. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.1549-07.2007 · Cited by 186 · see citing works
Degenerative and vascular lesions of the brain have synergistic effects in dementia of the elderly
Zekry, D., Duyckaerts, C. J., Moulias, R., Belmin, J., Geoffre, C., Herrmann, F. R., & Hauw, J. (2002) · Acta Neuropathologica · doi:10.1007/s00401-001-0493-5 · Cited by 184 · see citing works
Brain MAPS: An automated, accurate and robust brain extraction technique using a template library
Leung, K. K., Barnes, J., Marc Modat, A., Ridgway, G. R., Bartlett, J. W., Fox, N. C., & Sebastien Ourselin, A. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2010.12.067 · Cited by 178 · see citing works
Self-citationAngiotensins in Alzheimer's disease – friend or foe?
Kehoe, P. G., Miners, J. S., & Love, S. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2009.07.006 · Cited by 166 · see citing works
Self-citation(2009) · PubMed Central · Cited by 165 · see citing works
Self-citationMiners, J. S., Ashby, E., Helmond, Z. V., Chalmers, K. A., Palmer, L. E., Love, S., & Kehoe, P. G. (2007) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2007.00885.x · Cited by 165 · see citing works
Self-citationSudre, C. H., Cardoso, M. J., Bouvy, W. H., Biessels, G. J., Barnes, J., & Sebastien Ourselin, A. (2015) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2015.2419072 · Cited by 162 · see citing works
Protective Effects of Intranasal Losartan in the APP/PS1 Transgenic Mouse Model of Alzheimer Disease
Danielyan, L., Klein, R., Hanson, L. R., Buadze, M., Schwab, M. G., Gleiter, C. H., & Frey, W. H. (2010) · Rejuvenation Research · doi:10.1089/rej.2009.0944 · Cited by 158 · see citing works
Leung, K. K., Clarkson, M. J., Bartlett, J. W., Clegg, S., Jack, C. R., Weiner, M. W., Fox, N. C., & Sebastien Ourselin, A. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.12.059 · Cited by 158 · see citing works
Self-citationTEDESCO, M. (1999) · American Journal of Hypertension · doi:10.1016/s0895-7061(99)00156-9 · Cited by 142 · see citing works
Influence of losartan and atenolol on memory function in very elderly hypertensive patients
Fogari, R., Mugellini, A., Zoppi, A., Derosa, G., Pasotti, C., Fogari, E., & Preti, P. S. (2003) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001613 · Cited by 134 · see citing works
Telmisartan prevented cognitive decline partly due to PPAR-γ activation
Mogi, M., Li, J., Tsukuda, K., Iwanami, J., Min, L., Sakata, A., Fujita, T., Iwai, M., & Horiuchi, M. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.08.032 · Cited by 134 · see citing works
Zhou, J., Ando, H., Macova, M., Dou, J., & Saavedra, J. M. (2005) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600082 · Cited by 114 · see citing works
Miners, J. S., Baig, S., Tayler, H. M., Kehoe, P. G., & Love, S. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181afe475 · Cited by 111 · see citing works
Self-citationČulman, J., von Heyer, C., Piepenburg, B., Rascher, W., & Unger, T. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00983-2 · Cited by 99 · see citing works
Angiotensin II inhibits the release of [3H]acetylcholine from rat entorhinal cortex in vitro
Barnes, J. M., Barnes, N. M., Costall, B., Horovitz, Z. P., & Naylor, R. J. (1989) · Brain Research · doi:10.1016/0006-8993(89)90095-4 · Cited by 98 · see citing works
Assessing Utility of Single Photon Emission Computed Tomography (SPECT) Scan in Alzheimer Disease
DeKosky, S. T., Shih, W.-J., Schmitt, F. A., Coupal, J. J., & Kirkpatrick, C. (1990) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199040100-00002 · Cited by 88 · see citing works
Reduced sample sizes for atrophy outcomes in Alzheimer's disease trials: baseline adjustment
Schott, J., Bartlett, J., Barnes, J., Leung, K. K., Ourselin, S., & Fox, N. C. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.011 · Cited by 84 · see citing works
Self-citationAccurate measurement of brain changes in longitudinal MRI scans using tensor-based morphometry
Hua, X., Gutman, B. A., Boyle, C. P., Rajagopalan, P., Leow, A., Yanovsky, I., Kumar, A., Toga, A. W., Jack, C. R., Schuff, N. W., et al. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.01.079 · Cited by 80 · see citing works
Placebo-Controlled Trials of Blood Pressure–Lowering Therapies for Primary Prevention of Dementia
Staessen, J. A., Thijs, L., Richart, T., Odili, A. N., & Birkenhäger, W. H. (2010) · Hypertension · doi:10.1161/hypertensionaha.110.165142 · Cited by 80 · see citing works
Bias in tensor based morphometry Stat-ROI measures may result in unrealistic power estimates
Thompson, W., & Holland, D. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2010.11.092 · Cited by 78 · see citing works
Association of Plasma Aß Peptides with Blood Pressure in the Elderly
Lambert, J., Dallongeville, J., Ellis, K. A., Schraen‐Maschke, S., Lui, J. K., Laws, S. M., Dumont, J., Richard, F., Cottel, D., Berr, C., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018536 · Cited by 78 · see citing works
Algorithms, atrophy and Alzheimer's disease: Cautionary tales for clinical trials
Fox, N. C., Ridgway, G. R., & Schott, J. M. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.01.077 · Cited by 77 · see citing works
Self-citationLü, Y., Liu, P., Wen, W., Grubbs, C. J., Townsend, R., Malone, J. P., Lubet, R. A., & You, M. (2010) · PubMed Central · Cited by 72 · see citing works
Angiotensin II inhibits acetylcholine release from human temporal cortex: implications for cognition
Barnes, J. M., Barnes, N. M., Costall, B., Horovitz, Z. P., Ironside, J. W., Naylor, R. J., & Williams, T. J. (1990) · Brain Research · doi:10.1016/0006-8993(90)90294-l · Cited by 71 · see citing works
Angiotensin II Inhibits Cortical Cholinergic Function
Barnes, J. M., Barnes, N. M., Costall, B., Horovitz, Z. P., Ironside, J. W., Naylor, R. J., & Williams, T. J. (1990) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199008000-00009 · Cited by 63 · see citing works
McGuinness, B., Todd, S., Passmore, A. P., & Bullock, R. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.118505 · Cited by 57 · see citing works
Self-citationLinking cerebrovascular defense mechanisms in brain ageing and Alzheimer's disease
Kalaria, R. N. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.10.020 · Cited by 48 · see citing works
Imran, M. B., Kawashima, R., Awata, S., Sato, K., Kinomura, S., Ono, S., Sato, M., & Fukuda, H. (1999) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.228 · Cited by 46 · see citing works
ACE variants and association with brain Aβ levels in Alzheimer's disease.
Miners, J. S., Helmond, Z. V., Raiker, M., Love, S., & Kehoe, P. G. (2010) · PubMed Central · Cited by 43 · see citing works
Self-citationProgress in the development of new drugs in Alzheimer's disease
Piau, A., Nourhashémi, F., Hein, C., Caillaud, C., & Vellas, B. J. (2011) · The journal of nutrition health & aging · doi:10.1007/s12603-011-0012-x · Cited by 41 · see citing works
Hanon, O., Latour, F., Ml, S., Lenoir, H., Forette, F., & As, R. (2005) · PubMed · Cited by 41 · see citing works
Melbourne, A., Toussaint, N., Owen, D., Simpson, I., Anthopoulos, T., Vita, E. D., Atkinson, D., & Sebastien Ourselin, A. (2016) · Neuroinformatics · doi:10.1007/s12021-016-9297-6 · Cited by 37 · see citing works
Hajjar, I. M., Hart, M., Milberg, W., Novak, V., & Lipsitz, L. A. (2009) · BMC Geriatrics · doi:10.1186/1471-2318-9-48 · Cited by 35 · see citing works
Does the Angiotensin II Receptor Antagonist Losartan Improve Cognitive Function?
Tedesco, M. A., Ratti, G., Salvo, G. D., & Natale, F. (2002) · Drugs & Aging · doi:10.2165/00002512-200219100-00001 · Cited by 30 · see citing works
Guyonnet, S., van Kan, G. A., Andrieu, S., Aquino, J. P. R., Arbus, C., Becq, J.-P., Berr, C., Bismuth, S., Chamontin, B., DANTOINE, T. F., et al. (2008) · The journal of nutrition health & aging · doi:10.1007/bf02983204 · Cited by 26 · see citing works
Akatsu, H., Ogawa, N., Kanesaka, T., Hori, A., Yamamoto, T., Matsukawa, N., & Michikawa, M. (2010) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2010.09.030 · Cited by 24 · see citing works
Hong, K., Kang, D., Bae, H., Kim, Y., Han, M., Park, J., Rha, J., Lee, Y., Koo, J., Cho, Y., et al. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2009.01299.x · Cited by 20 · see citing works
Shiraishi, H., Chang, C., Kanno, H., & Yamamoto, I. (2003) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2003.02.013 · Cited by 16 · see citing works
Chronic treatment with Losartan and Cerebral Ischemic Tolerance
Zhao, Z., Tuor, U. I., & Barber, P. A. (2009) · Journal of Experimental Stroke and Translational Medicine · doi:10.4172/1939-067x.1000110 · Cited by 2 · see citing works
Flagged first, then by citations
1 of the 79 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Miners JS, Baig S, Palmer J, Palmer LE, Kehoe PG, Love S. Abeta-degrading enzymes in Alzheimer's disease. Brain Pathol. 2008;18(2):240-52.
Cited by
Sorted by citations
Alzheimer Disease Genetics Consortium (ADGC), Kunkle, B. W., The European Alzheimer’s Disease Initiative (EADI), Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium (CHARGE), Genetic and Environmental Risk in AD/Defining Genetic, P. A. E. R. F. A. D. C. (., Grenier-Boley, B., Sims, R., Bis, J. C., Damotte, V., Naj, A. C., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0358-2 · Cited by 2,946 · see citing works
Self-citationRecent advances on drug development and emerging therapeutic agents for Alzheimer’s disease
Athar, T., Balushi, K. A. A., & Khan, S. A. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06512-9 · Cited by 261 · see citing works
Drug repositioning and repurposing for Alzheimer disease
Ballard, C., Aarsland, D., Cummings, J., O’Brien, J., Mills, R., Molinuevo, J. L., Fladby, T., Williams, G., Doherty, P., Corbett, A., et al. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0397-4 · Cited by 201 · see citing works
Evans, C. E., Miners, J. S., Piva, G., Willis, C. L., Heard, D. M., Kidd, E. J., Good, M. A., & Kehoe, P. G. (2020) · Acta Neuropathologica · doi:10.1007/s00401-019-02098-6 · Cited by 148 · see citing works
Self-citationKehoe, P. G. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-171119 · Cited by 133 · see citing works
Self-citationBrain Renin–Angiotensin System at the Intersect of Physical and Cognitive Frailty
Cosarderelioglu, C., Nidadavolu, L. S., George, C. J., Oh, E. S., Bennett, D. A., Walston, J. D., & Abadir, P. M. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.586314 · Cited by 134 · see citing works
Gouveia, F., Camins, A., Ettcheto, M., Bicker, J., Falcão, A. C., Cruz, M. T., & Fortuna, A. C. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101612 · Cited by 96 · see citing works
Barthold, D., Joyce, G., Wharton, W., Kehoe, P. G., & Zissimopoulos, J. (2018) · PLoS ONE · doi:10.1371/journal.pone.0206705 · Cited by 89 · see citing works
Self-citationCerebral Hypoperfusion and the Energy Deficit in A lzheimer's Disease
Love, S., & Miners, J. S. (2016) · Brain Pathology · doi:10.1111/bpa.12401 · Cited by 82 · see citing works
The depressor axis of the renin–angiotensin system and brain disorders: a translational approach
Gironacci, M. M., Vicario, A., Cerezo, G., & Silva, M. G. (2018) · Clinical Science · doi:10.1042/cs20180189 · Cited by 60 · see citing works
Kehoe, P. G., Turner, N. L., Howden, B., Jarutytė, L., Clegg, S., Malone, I. B., Barnes, J., Nielsen, C. F., Sudre, C. H., Wilson, A., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00263-5 · Cited by 59 · see citing works
Self-citationRibeiro, V. T., de Souza, L. C., & Silva, A. C. S. E. (2019) · Protein and Peptide Letters · doi:10.2174/0929866527666191230103739 · Cited by 50 · see citing works
Recent Advances in the Endogenous Brain Renin-Angiotensin System and Drugs Acting on It
Aswar, U. M., Patil, R., Nilam, G., & Bodhankar, S. L. (2021) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1155/2021/9293553 · Cited by 43 · see citing works
Clement, C., Selman, L. E., Kehoe, P. G., Howden, B., Lane, J. A., & Horwood, J. P. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190146 · Cited by 42 · see citing works
Self-citationRoyea, J., Lacalle‐Aurioles, M., Trigiani, L. J., Fermigier, A., & Hamel, É. (2020) · Hypertension · doi:10.1161/hypertensionaha.119.14431 · Cited by 31 · see citing works
Comparison of Antihypertensive Drug Classes for Dementia Prevention
Walker, V. M., Davies, N. M., Martin, R. M., & Kehoe, P. G. (2020) · Epidemiology · doi:10.1097/ede.0000000000001245 · Cited by 30 · see citing works
Self-citationThe relation between antihypertensive treatment and progression of cerebral small vessel disease
Su, C., Wu, H., Yang, X., Zhao, B. T., & Zhao, R. (2021) · Medicine · doi:10.1097/md.0000000000026749 · Cited by 28 · see citing works
Rocha, N. P., Toledo, A. A. S. F., Corgosinho, L. T. S., de Souza, L. C., Guimarães, H. C., Resende, E. D. P. F., Braz, N. F. T., Gomes, K. B., Silva, A. C. S. E., Caramelli, P., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180282 · Cited by 27 · see citing works
Contrasting Metabolic Insufficiency in Aging and Dementia
Turner, D. A. (2021) · Aging and Disease · doi:10.14336/ad.2021.0104 · Cited by 25 · see citing works
Moran, C., Xie, K., Poh, S., Chew, S. C. J., Beare, R. J., Wang, W., Callisaya, M. L., & Srikanth, V. K. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180943 · Cited by 21 · see citing works
An introduction to therapeutic approaches to vascular cognitive impairment
Hainsworth, A. H., Elahi, F. M., & Corriveau, R. A. (2021) · Cerebral Circulation - Cognition and Behavior · doi:10.1016/j.cccb.2021.100033 · Cited by 19 · see citing works
Kunkle, B., Grenier-Boley, B., Sims, R., Bis, J., Naj, A., Boland, A., Vronskaya, M., van der Lee, S., Amlie-Wolf, A., Bellenguez, C., et al. (2018) · doi:10.1101/294629 · Cited by 35 · see citing works
Self-citationAn update on magnetic resonance imaging markers in AD
Leocadi, M., Canu, E., Calderaro, D., Corbetta, D., Filippi, M., & Agosta, F. (2020) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286420947986 · Cited by 17 · see citing works
The Neurovascular Unit in Dementia: An Opinion on Current Research and Future Directions
Beishon, L., & Panerai, R. B. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.721937 · Cited by 17 · see citing works
Marcolini, S., Frentz, I., Sánchez-Catasús, C. A., Mondragón, J. D., Feltes, P. K., van der Hoorn, A., Borra, R., Ikram, M. A., Dierckx, R., & Deyn, P. P. D. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101661 · Cited by 15 · see citing works
Drug interactions with dementia‐related pathophysiological pathways worsen or prevent dementia
Barus, R., Béné, J., Deguil, J., Gautier, S., & Bordet, R. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14607 · Cited by 12 · see citing works
Recent Updates on the Development of Therapeutics for the Targeted Treatment of Alzheimer’s Disease
Rajput, S., Malviya, R., Bahadur, S., & Puri, D. (2023) · Current Pharmaceutical Design · doi:10.2174/0113816128274618231105173031 · Cited by 11 · see citing works
Alzheimer’s Disease Pharmacology
Plascencia‐Villa, G., & Perry, G. L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00018-9 · Cited by 6 · see citing works
Kehoe, P. G., Turner, N. L., Howden, B., Jarutyt, L., Clegg, S., Malone, I. B., Barnes, J., Nielsen, C. F., Sudre, C. H., Wilson, A., et al. (2021) · Efficacy and Mechanism Evaluation · doi:10.3310/eme08190 · Cited by 7 · see citing works
Self-citationPotential role of Drug Repositioning Strategy (DRS) for management of tauopathy
Zaki, M. O., Elsherbiny, D. A., Salama, M., & Azab, S. S. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.120267 · Cited by 5 · see citing works
Marcum, Z. A., Hohl, S. D., Gray, S. L., Barthold, D., Crane, P. K., & Larson, E. B. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181080 · Cited by 4 · see citing works
Yan, R. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735170868.793558625 · Cited by 2 · see citing works
Jarutytė, L., Petr, J., Turner, N. L., Kehoe, P. G., Mutsaerts, H. J. M. M., & Thomas, D. L. (2025) · Cerebral Circulation - Cognition and Behavior · doi:10.1016/j.cccb.2024.100376 · Cited by 1 · see citing works
Self-citationThe Contribution of the Renin-Angiotensin System to Alzheimer’s Disease
Güzel, Ö., & Kehoe, P. G. (2024) · Current topics in behavioral neurosciences · doi:10.1007/7854_2024_525
Self-citationTransforming Alzheimer's Treatment: Unveiling New Potential with Drug Repurposing Strategies
Mishra, A. S., Vasanthan, M. V. M., Ghosh, B., & Sivakumar, P. M. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673341391241231054936
- Authors
- Kehoe, P. G., Blair, P. S., Howden, B., Thomas, D. L., Malone, I. B., Horwood, J., Clement, C., Selman, L. E., Baber, H., Lane, A., Coulthard, E., Passmore, A. P., Fox, N. C., Wilkinson, I. B., & Ben-Shlomo, Y.
- Affiliations
- Southmead Hospital (GB)
- University of Bristol (GB)
- National Hospital for Neurology and Neurosurgery (GB)
- UCL Queen Square Institute of Neurology (GB)
- Bristol Randomised Trials Collaboration (BRTC), Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
- Queen's University Belfast (GB)
- University of Cambridge (GB)
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
- Corresponding author
- Kehoe, Patrick G.
- ORCID
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2017-12-19
- Volume
- 61
- Issue
- 2
- Pages
- 803-814
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2773442741
- Cited by
- 35
- References
- 79
- Citations by year
- 2025: 2 · 2024: 1 · 2023: 1 · 2022: 2 · 2021: 10 · 2020: 6 · 2019: 7 · 2018: 5 · 2016: 1
- FWCI
- 4.04
- Type
- journal article
- Language
- en
- Open access
- Licence
- cc-by-nc
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- Explore Bristol Research (publishedVersion, cc-by-nc)
- Bristol Research (University of Bristol) (submittedVersion, cc-by-nc)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Eli Lilly and Company
- Biogen
- National Institute for Social Care and Health Research
- Alzheimer's Society
- National Institute for Health and Care Research (11/47/03, NF-SI-0513-10134, NF-SI-0515-10093)
- British Heart Foundation (FS/12/33/29561, FS/07/001/21990, FS/12/8/29377)
- Public Health Agency
- North Bristol NHS Trust
- Medical Research Council (MR/K025643/1)
- Efficacy and Mechanism Evaluation Programme (11/47/03)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Keywords
- Alzheimer's disease, losartan
- MeSH terms
- Activities of Daily Living, Alzheimer Disease, Antihypertensive Agents, Atrophy, Brain, Double-Blind Method, Female, Humans, Magnetic Resonance Imaging, Male, Quality of Life, Regression Analysis, Renin-Angiotensin System, Multicenter Studies as Topic, Blood Pressure Monitors, Multivariate Analysis, Randomized Controlled Trials as Topic, Clinical Trials, Phase II as Topic, Disease Progression, Losartan
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
